Crossmark

Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment

Crossref DOI link: https://doi.org/10.1007/s10792-021-02188-z

Published Online: 2022-01-30

Published Print: 2022-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Süren, Elçin https://orcid.org/0000-0001-8904-9828
Özkaya, Dilek https://orcid.org/0000-0002-3523-8479
Çetinkaya, Ersan https://orcid.org/0000-0002-6876-554X
Kalaycı, Mustafa https://orcid.org/0000-0001-8056-6634
Yiğit, Kenan https://orcid.org/0000-0001-9330-7965
Kücük, Mehmet Fatih https://orcid.org/0000-0002-2548-7869
Erol, Muhammet Kazim https://orcid.org/0000-0002-1720-8065
License Information

Text and Data Mining valid from 2022-01-30

Version of Record valid from 2022-01-30
More Information

Article History

Received: 14 August 2021

Accepted: 18 December 2021

First Online: 30 January 2022